Our firm celebrated its Centennial in 2017. We practice exclusively in the area of intellectual property law, which encompasses patents, trademarks, copyrights, trade secrets and related business and litigation issues. For over 100 years, we have represented diverse clients, including Fortune 500 companies and individual entrepreneurs.
Renner Kenner has obtained thousands of patents over the years for our clients. The "This Week in Our History...” section below is an example of a patent that was written and/or prosecuted by Renner Kenner.
The U.S. Patent and Trademark Office issued U.S. Patent No. 9,492,470 on November 15, 2016 to Miami University. The patent is entitled “Use of HMGA-targeted phosphorothioate DNA Aptamers To Suppress Carcinogenic Activity And Increase Sensitivity To Chemotherapy Agents In Human Cancer Cells.” Elevated high mobility group A (HMGA) protein expression in human cancer cells, and especially human pancreatic cancer cells, is correlated with resistance to the chemotherapy agent gemcitabine. The invention uses HMGA-targeted AT-rich phosphorothioate DNA (AT-sDNA) aptamers to suppress HMGA carcinogenic activity. The data indicates the potential use of HMGA targeted DNA aptamers to enhance chemotherapy efficacy in human cancer treatment, and in particular human pancreatic cancer treatment.
Renner Kenner proudly supports the Akron Children’s Hospital Rehabilitative Services Team via The Brandon Thomas Clark Fund. Akron Children’s Rehabilitative Services Team works with infants, children, and teens requiring therapy following an illness or injury; those managing the effects of a chronic condition such as cerebral palsy or autism spectrum disorders; adult patients with burns, cystic fibrosis and hemophilia; and individuals being treated in Akron Children's Pain Center. The Brandon Thomas Clark Fund supports the needs of Rehabilitative Services for patients and their families. Visit https://www.akronchildrens.org/cms/rehabilitative_services/ to see how you can help too!
